Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $293 | In Stock | |
2 mg | $436 | In Stock | |
5 mg | $722 | In Stock | |
10 mg | $987 | In Stock | |
25 mg | $1,520 | In Stock | |
50 mg | $1,980 | In Stock |
Description | ME-3221 is an angiotensin AT1 receptor antagonist that prevents hypertensive complications in aged stroke-prone hypertensive rats. |
In vivo | ME3221 inhibited the pressor response to angiotensin II in rats at doses of 0.3-1.0 mg/kg. Higher doses of ME3221 (3-10 mg/kg) were required to achieve the same inhibitory potency in dogs.The antagonistic potency of ME3221 against angiotensin II-induced contraction in rabbit aorta (pA2 = 8.82) was approximately fivefold higher than in canine aorta (pA2 = 8.18).[1];Long-term (8 months) oral administration of ME3221 (10 mg/kg/d) to aged (32 weeks) stroke-prone hypertensive rats (SHRSP) suppressed mortality and hypertensive complications observed in control SHRSP: stroke (hemorrhage, spongiosis and flaccidity in the cerebral cortex), increased proteinuria, total N-acetyl-β-D-glucosaminidase activity and cardiac hypertrophy and pleural effusion. [2];SHRSP were orally administered ME3221 (3 and 10 mg/kg per day) from 6 to 20 weeks, and ME3221 inhibited to a considerable extent the elevation of SBP in salt-containing SHRSP, increased survival to >90%, and reduced hypertensive complications such as stroke (moderate), renal injury (increased proteinuria and total N-acetyl-β-D-glucosaminidase activity), and heart failure (cardiac hypertrophy and pleural effusion). [3] |
Alias | ME 3221, ME3221 |
Molecular Weight | 387.43 |
Formula | C22H21N5O2 |
Cas No. | 139958-16-0 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.